Philippe Guillaume

Title: Philippe Guillaume: Inventor in Cancer Research

Introduction

Philippe Guillaume is an inventor associated with Les Hôpitaux-Vieux, France, and Ludwig Institute for Cancer Research Limited. His work includes inventions concerning reversible protein multimers, with applications in research, diagnostics, and therapy. He is credited with 2 patents.

Latest Patents

The supplied patent information describes inventions titled “Reversible protein multimers, methods for their production and use.” These disclosures focus on protein multimers whose monomeric proteins are attached to a carrier molecule through chelation complex bonds. The multimers are designed to remain stable under physiological conditions while allowing controlled dissociation under physiological, nontoxic conditions.

One described application is the use of reversible major histocompatibility complex (MHC) multimers to detect and isolate specific T cells or T-cell populations. Because the multimers can be dissociated efficiently, they can reduce the duration of MHC binding to T-cell receptors and thereby minimize receptor-mediated T-cell activation. This approach may help researchers isolate antigen-specific CD8+ T cells, including rare cells with high-affinity receptors for tumor antigens, while reducing the risk of activation-dependent cell death.

Career Highlights

Guillaume’s patent work addresses tools for studying and handling immune cells. The described reversible multimers are intended for in vitro, ex vivo, and in vivo applications, supporting potential uses across research, diagnostics, and therapy. His work is associated with Ludwig Institute for Cancer Research Limited.

Collaborations

The supplied information identifies Immanuel F. Luescher and Julien Schmidt as Guillaume’s coworkers. Their names are associated with the patent work on reversible protein multimers.

Conclusion

Philippe Guillaume’s inventions focus on controllable protein multimers and their potential to support the detection and isolation of valuable antigen-specific T cells. These patented approaches connect molecular design with possible applications in cancer research and therapeutic development.